Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and lowers the price target from $48 to $47.

May 03, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush maintains a Neutral rating on Ultragenyx Pharmaceutical and lowers the price target from $48 to $47.
The adjustment in price target by a notable analyst like Laura Chico from Wedbush, while maintaining a Neutral rating, suggests a minor adjustment in valuation expectations without a significant change in the company's overall outlook. This is likely to have a neutral short-term impact on the stock as the market absorbs the slight adjustment in expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100